Actinium Pharmaceuticals, Inc. — Q2 2015 Form 10-Q
Business context and reporting period. This unaudited filing covers the quarter and six months ended June 30, 2015. Actinium is a clinical-stage biotechnology company developing antibody-based radioimmunotherapies, including Actimab-A and Iomab-B. It has no approved products, commercial sales, or recurring revenue; development depends on clinical trials, collaborators, and contract manufacturers.
Financial results and liquidity
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $3.84 million | $7.89 million |
| General and administrative | $3.55 million | $7.36 million |
| Total operating expenses / operating loss | $7.40 million / $(7.40) million | $15.27 million / $(15.27) million |
| Net income (loss) | $(7.46) million | $(10.54) million |
| Basic and diluted loss per share | $(0.20) | $(0.30) |
Cash flow and balance sheet. Six-month operating cash use was $11.08 million, investing cash use was $959, and financing provided $30.33 million, primarily from stock sales. Cash and cash equivalents were $25.95 million at June 30, up from $6.71 million at December 31, 2014. Current assets were $26.21 million and current liabilities $3.05 million. Total liabilities were $3.05 million, including $92,267 of notes payable and $1.92 million of warrant derivative liabilities. Stockholders’ equity was $23.28 million; accumulated deficit was $101.74 million.
There is no meaningful revenue margin to assess. The company reported no commercial revenue and has no current recurring source of revenue to cover operating costs. Cash runway statements differ: MD&A says cash is sufficient through the next 12 months, while the risk discussion specifies through the second quarter of 2016. Both are management estimates, not a guarantee.
Changes versus comparable periods
- Quarterly operating expenses rose to $7.40 million from $4.42 million a year earlier. R&D increased by about $1.7 million, reflecting Iomab-B manufacturing, payroll, and Actimab-A costs; G&A increased by about $1.3 million, mainly payroll and consulting.
- Quarterly net results shifted from $3.52 million income in Q2 2014 to a $7.46 million loss in Q2 2015. The prior-year quarter included a $7.94 million gain from revaluing warrant derivative liabilities; Q2 2015 recorded a $58,000 loss on that item.
- Six-month operating expenses increased to $15.27 million from $8.56 million. R&D rose by about $4.2 million, primarily due to BC8 manufacturing costs and salaries; G&A rose by about $2.5 million, mainly payroll and consulting.
- Six-month net loss narrowed to $10.54 million from $13.18 million, principally because of a $4.74 million derivative fair-value gain in 2015 versus a $4.62 million loss in 2014. These valuation changes are sensitive to the company’s share price and are not operating cash flows.
- Operating cash use increased to $11.08 million from $5.06 million, while cash raised through financing increased to $30.33 million from $14.33 million.
Funding, outlook, risks and unusual items
- The company raised approximately $18.5 million net in a February 2015 offering and $4.48 million net in a June registered direct offering. It also reported approximately $7.51 million net from shares sold under its sales agreement during Q2. These financings increased share count and create dilution risk; 40,486,876 shares were outstanding at June 30, 2015.
- Management expected R&D and G&A costs to increase. It estimated approximately $7 million in direct costs to complete the ongoing Actimab-A Phase 1/2 trial and $25–30 million to complete the anticipated Iomab-B pivotal trial, with completion anticipated in 2017. The company intended to request FDA permission to enter the Iomab-B pivotal trial in 2015.
- Key execution risks include clinical-trial outcomes and patient enrollment, regulatory approval, reliance on third-party manufacturing and collaborators, intellectual-property protection, and access to actinium-225. The ORNL isotope-supply contract ran through year-end 2015 and required renewal. Iomab-B was disclosed as not patent-protected.
- Contractual and contingent costs include approximately $1.8 million remaining under the Goodwin manufacturing agreement, future trial and research spending, and milestone and royalty obligations under licensing agreements. The Iomab-B trial estimate is materially larger than available cash and may require additional financing or partnering.
- Warrant derivative liabilities are Level 3 fair-value measurements using management assumptions; changes can materially affect reported earnings. Stock-based compensation was $5.17 million for the first half of 2015.
- After quarter-end, the board approved plan amendments providing accelerated vesting on a change of control and amended executive/consulting agreements that enhanced severance and vesting provisions. Bylaw changes established advance-notice requirements for shareholder proposals and director nominations. The filing reported no legal proceedings and no material off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the cash runway assumption and reconcile the filing’s “next 12 months” statement with its more specific estimate through Q2 2016.
- Track actual trial progress, FDA interactions, enrollment, safety findings, and whether the stated trial timelines and cost estimates remain current.
- Assess whether additional financing or a commercial partner will be needed, and the resulting dilution or rights surrendered.
- Verify renewal and continuity of actinium-225 supply, manufacturing readiness, and remaining commitments to contract manufacturers and licensors.
- Review warrant derivative valuation assumptions and the potential impact of share-price changes, as well as dilution from outstanding options and warrants.